Table 1.
Demographic and clinical characteristics of the patients.
| Demographic and clinical characteristics of the patients | |
|---|---|
| Characteristics | |
| Patients | n = 23 |
| Age (years) | 62·1 ± 14·1 |
| Age (range) | 26 - 81 |
| Sex - Male (%) | 73·9 |
| BMI, kg/m2 | 29·3 ± 4·8 |
| Mean duration of symptoms before admission (days) | 6·4 ± 3·2 |
| Mean duration of symptoms before intubation (days) | 7·6 ± 3·7 |
| Number of patients with high-flow nasal oxygen (no intubation) | 5 |
| Number of patients with ECMO | 3 |
| Hospital mortality rate (%) * | 29·2 |
| Hospital mortality rate of patients with high-flow nasal oxygen (%) | 20·0 |
| Hospital mortality rate of ECMO patients (%) | 0·0 |
| Length of Stay (days)* | 35·7 ± 32·2 |
| Length of Stay of patients with high-flow nasal oxygen (days) | 14·2 ± 5·8 |
| Length of Stay of ECMO patients (days) | 70·7 ± 36·9 |
| Percentage of all patients who received intermittently muscle relaxants (%) | 30·4 |
| Percentage of ECMO patients who received intermittently muscle relaxants (%) | 100·0 |
| Percentage of all patients who received intermittently norepinephrine and vasopressin (%) | 30·4 |
| Percentage of ECMO patients who received intermittently norepinephrine and vasopressin (%) | 66·7 |
| APACHE II | 18·0 ± 9·4 |
| SOFA all patients | 6·3 ± 4·9 |
| SOFA of patients with high-flow nasal oxygen (no intubation) | 2·2 ± 1·3 |
| SOFA of patients with ECMO | 11·0 ± 5·3 |
| COVID-19 symptoms - no. (%) | |
| Dyspnea | 19 (82·6) |
| Cough | 18 (78·3) |
| Sore throat | 3 (13) |
| Fever | 22 (95·7) |
| Myalgia | 9 (39·1) |
| Exhaustion | 13 (56·5) |
| Coexisting conditions - no. (%) | |
| COPD | 3 (13·0) |
| Asthma | 1 (4·3) |
| Other lung disease | 3 (13·0) |
| Pre-obesity | 10 (43·5) |
| Obesity | 8 (34·8) |
| Arterial hypertension | 18 (78·3) |
| Diabetes mellitus Type 2 | 9 (39·1) |
| Coronary heart disease | 2 (8·7) |
| HIV, transplantation or immuno-supressive medications | 2 (8·7) |
| Subset 1 (Intubation group) | |
| Patients | 10 |
| Age (years) | 70·4 ± 10·8 |
| Sex - Male (%) | 80 |
| BMI, kg/m2 | 28·4 ± 4·5 |
| Mean duration of symptoms before admission (days) | 7·2 ± 4·3 |
| Mean duration of symptoms before intubation (days) | 8·7 ± 4·2 |
| Hospital mortality rate (%) | 40·0 |
| Length of Stay (days)* | 38·3 ± 26·1 |
| Percentage of patients who received intermittently muscle relaxants (%) | 40·0 |
| Percentage of patients who received intermittently norepinephrine and vasopressin (%) | 30·0 |
| APACHE II | 17·8 ± 9·4 |
| SOFA | 3·9 ± 2·9 |
| Subset 2 (PEEP trial group) | |
| Patients | 7 |
| Age (years) | 61·4 ± 15·8 |
| Sex - Male (%) | 57·1 |
| BMI, kg/m2 | 30·0 ± 6·5 |
| Mean duration of symptoms before admission (days) | 5·7 ± 2·6 |
| Mean duration of symptoms before intubation (days) | 6·7 ± 2·7 |
| Hospital mortality rate (%) | 42·9 |
| Length of Stay (days) | 56·3 ± 32·9 |
| Percentage of patients who received intermittently muscle relaxants (%) | 28·6 |
| Percentage of patients who received intermittently norepinephrine and vasopressin (%) | 28·6 |
| APACHE II | 20·7 ± 8·8 |
| SOFA | 5·7 ± 5·2 |
| Respiratory rate/ min | 16·0 ± 2·6 |
| Subset 3 (Prone position group) | |
| Patients | 9 |
| Age (years) | 62·0 ± 14·2 |
| Sex - Male (%) | 66 |
| BMI, kg/m2 | 30·4 ± 6·5 |
| Mean duration of symptoms before admissions (days) | 6·7 ± 4·8 |
| Mean duration of symptoms before intubation (days) | 7·2 ± 4·8 |
| Hospital mortality rate (%) | 55·6 |
| Length of Stay (days)a | 50·4 ± 34·9 |
| Percentage of patients who received intermittently muscle relaxants (%) | 55·6 |
| Percentage of patients who received intermittently norepinephrine and vasopressin (%) | 44·4 |
| APACHE II | 26·2 ± 6·5 |
| SOFA | 7·4 ± 4·9 |
| Mean time to first prone positioning (days) | 3 ± 3·9 |
| Duration of each prone positioning (hours) | 15·4 ± 2·5 |
Values are means ± SD. COPD, chronic obstructive pulmonary disease; COVID-19, coronavirus disease 2019; APACHE II, Acute Physiology And Chronic Health Evaluation II; SOFA, Sepsis-related organ failure assessment score. APACHE II and SOFA score were obtained at admissions day. #One patient is still hospitalized and thus excluded from the hospital mortality rate.
a
One patient is still hospitalized and excluded from hospital mortality rate and length of stay analyses.